A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).

被引：4

作者：

Aggarwal, Rahul Raj

Eggener, Scott E.

Chen, Ronald C.

Heller, Glenn

Patnaik, Akash

Xiao, Han

Weckstein, Douglas

Mohler, James

Watson, Mark

Taplin, Mary-Ellen

Skoog-Sluman, Linda A.

Pereji, Meryl

Aikins-Afful, Eunice

Parsons, J. Kellogg

Ryan, Charles J.

Morris, Michael J.

机构：

[1] UC San Francisco, Helen Diller Family Comprehens Ctr, San Francisco, CA USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Univ N Carolina, Chapel Hill, NC 27515 USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Beth Israel Deaconess Med Ctr, Dana Farber Canc Inst, Boston, MA 02215 USA

[6] Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA

[7] New Hampshire Oncol Hematol PA, Hooksett, NH USA

[8] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[9] Washington Univ, Sch Med, St Louis, MO USA

[10] Dana Farber Canc Inst, Boston, MA 02115 USA

[11] Univ Chicago, Hinsdale, IL USA

[12] Alliance Fdn Trials LLC, Boston, MA USA

[13] UCSD Moores Canc Ctr, La Jolla, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS5090

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5090

引用

页数：1